

Revolutionary approach to diagnostic testing for resource-limited settings.



Hologic
global access
initiative

Global Access Initiative is our solution to mitigating the burden of viral diseases in areas of high prevalence. This cost-effective and financially sustainable program aims to transform the world of diagnostics by improving access to critical infectious disease testing.

**All-inclusive testing:
No upfront cost or capital expenditure.**

\$12.00 per patient test
includes*:

- ✓ Instrument placement†
- ✓ Reagents and consumables
- ✓ Service and maintenance
- ✓ Freight and logistics
- ✓ Replacement tests‡



**Aptima® assays on
the Panther® system.**

As part of our commitment to the 2030 UNAIDS 95-95-95 goals¹, the Global Access Initiative includes HIV-1 testing and other viral targets. Qualified assays include:

Aptima® HIV-1 Quant Dx Assay

Aids in the diagnosis, confirmation and clinical management of HIV-1 infection. WHO prequalified.

Aptima® HCV Quant Dx Assay

Aids in the diagnosis, confirmation and clinical management of HCV infection.

Aptima® HBV Quant Assay

Aids in the clinical management of HBV infection.

Aptima® HPV Assay

Detects 14 high-risk HPV types.

Aptima® SARS-CoV-2 Assay

Detects SARS-CoV-2 infection.

* Testing services do not include ancillary costs, for example those associated with sample collection, sample transport, laboratory staff time, laboratory infrastructure, generic laboratory supplies (e.g., primary collection tubes, disposable gloves, bleach, bleach bottles, bleach enhancer, waste bottles, etc.), inventory management, or general administration and overhead costs.

† For the Aptima SARS-CoV-2 assay, terms apply to existing Panther system footprint only, subject to review on case-by-case basis.

‡ Free-of-charge replacement of tests that fail due documented instrument errors (includes one set of controls and calibrators per kit).

Expand testing in your space.

Infrastructure Requirements

To participate in the Hologic Global Access Initiative, laboratories must meet certain infrastructure requirements.



Physical Space

Sufficient space to accommodate the Panther system: 122 cm (w) x 81.5 cm (d) x 175 cm (h). Sufficient space to accommodate a rocker, centrifuge and cold storage for additional samples and reagents.



Electrical Requirements

An electrical connection that supports up to a 1400 W draw, with a dedicated 20-amp circuit.[‡] A backup generator capable of supporting all equipment.



Air Conditioning

Central or wall-mounted air conditioning with adequate capacity to maintain a temperature between 15°C to 30°C and relative humidity from 20%-85%.



Sink

A sink or washbasin for liquid-waste disposal.



Waste Management

Liquid waste is nonhazardous and does not require special handling.[§]



Refrigerator

One or more refrigerator(s) with temperature control, maintained at 2°C to 8°C, to store samples and reagents.



Freezer

One or more freezer(s) with temperature control, maintained at -15°C to -35°C, to store calibrators and controls.

Testing Volume Requirements

To be eligible for the Hologic Global Access Initiative, the purchasing country or organization must share a site-specific forecast for any new Panther system placement, which anticipates:

- Processing volumes that contribute to a national average of 30,000 patient samples per eligible instrument per year within 12 months of placement.^{||}

Global health solutions for the way we live.

[hologichumancare.com](https://www.hologichumancare.com)

Eligible Countries**

Angola
Benin
Botswana
Burkina Faso
Burundi
Cambodia
Cameroon
Cape Verde
Central African Republic
Comoros
Congo
Democratic Rep. of the Congo (DRC)
Egypt
Eswatini
Ethiopia
Gambia
Ghana
Guinea
Guinea-Bissau
Haiti
India
Indonesia
Ivory Coast
Jamaica
Kenya
Laos
Lesotho
Liberia
Malawi
Malaysia
Mali
Mauritania
Mongolia
Mozambique
Myanmar
Namibia
Nepal
Nigeria
Pakistan
Papua New Guinea
Rwanda
South Africa
Sri Lanka
Tanzania
Timor-Leste
Togo
Uganda
Vietnam
Zambia
Zimbabwe

[‡] Hologic will provide an uninterruptible power supply and surge protector and make necessary electrical modifications during installation.

[§] Inclusive of all eligible assays and sample types.

^{||} Follow local and state guidelines.

** List of eligible countries is for initiative participation. Not all assays are available in each of the countries listed.

References: 1. UNAIDS. Understanding Fast-Track: Accelerating Action to End the AIDS Epidemic by 2030. https://www.unaids.org/sites/default/files/media_asset/JC2686_WAD2014report_en.pdf. Published June 2015. Accessed April 28, 2021.

SS-00757-001 Rev. 003 © 2022 Hologic, Inc. All rights reserved. Hologic, Aptima, Panther and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. This information is intended for medical professionals and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshow, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative or write to humancare@hologic.com.